RHHBY

Cue the Biotech M&A Attack!

A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road. More

3 New Biotech Buys for Your Portfolio

Three new biotech buys lead the way for additions to your portfolio as we head into April. More

Analysts Run the Apple Asylum — Tuesday’s IP Market Recap

Price targets keep climbing to the moon: $715, $910 -- even $1,001. More

Here Comes a Bidding War for Amylin

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share. More

Generic Versions of Boniva Approved By the FDA

The FDA approved the first generic versions of osteoporosis drug Boniva, allowing manufacturers like Apotex, Orchid Healthcare and Mylan to make the drug. More

Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World

Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends. More

Why Illumina’s Future Remains Bright

Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects. More